TABLE 3.
Summary of very major and major errors in antimicrobial susceptibility
| Antibiotic | No. of VMEsa |
No. of MEsb |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Resolved to AXDX | Resolved to SOC | Resolved to neither | Unresolved | Total | Resolved to AXDX | Resolved to SOC | Resolved to neither | Unresolved | |
| Gram-positive organisms | ||||||||||
| Erythromycin | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Linezolid | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gram-negative organisms | ||||||||||
| Ampicillin-sulbactam | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cefepime | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Ceftazidime | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Ciprofloxacin | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ertapenem | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Resistance phenotype tests | ||||||||||
| Cefoxitin (methicillin resistance) | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Total | 8 | 4 | 1 | 3 | 0 | 4 | 1 | 2 | 1 | 0 |
a
VME, very major error.
b
ME, major error.